PMC:7600245 / 54155-55109 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T237","span":{"begin":92,"end":103},"obj":"Body_part"},{"id":"T238","span":{"begin":170,"end":177},"obj":"Body_part"},{"id":"T239","span":{"begin":261,"end":273},"obj":"Body_part"},{"id":"T240","span":{"begin":393,"end":405},"obj":"Body_part"},{"id":"T241","span":{"begin":457,"end":468},"obj":"Body_part"},{"id":"T242","span":{"begin":577,"end":585},"obj":"Body_part"}],"attributes":[{"id":"A237","pred":"fma_id","subj":"T237","obj":"http://purl.org/sig/ont/fma/fma63849"},{"id":"A238","pred":"fma_id","subj":"T238","obj":"http://purl.org/sig/ont/fma/fma67116"},{"id":"A239","pred":"fma_id","subj":"T239","obj":"http://purl.org/sig/ont/fma/fma63849"},{"id":"A240","pred":"fma_id","subj":"T240","obj":"http://purl.org/sig/ont/fma/fma63849"},{"id":"A241","pred":"fma_id","subj":"T241","obj":"http://purl.org/sig/ont/fma/fma63849"},{"id":"A242","pred":"fma_id","subj":"T242","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T234","span":{"begin":231,"end":237},"obj":"Disease"},{"id":"T235","span":{"begin":375,"end":379},"obj":"Disease"},{"id":"T236","span":{"begin":446,"end":455},"obj":"Disease"},{"id":"T237","span":{"begin":603,"end":611},"obj":"Disease"},{"id":"T238","span":{"begin":614,"end":623},"obj":"Disease"},{"id":"T239","span":{"begin":740,"end":748},"obj":"Disease"},{"id":"T240","span":{"begin":783,"end":818},"obj":"Disease"},{"id":"T241","span":{"begin":789,"end":818},"obj":"Disease"},{"id":"T242","span":{"begin":930,"end":938},"obj":"Disease"}],"attributes":[{"id":"A234","pred":"mondo_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A235","pred":"mondo_id","subj":"T235","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A236","pred":"mondo_id","subj":"T236","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A237","pred":"mondo_id","subj":"T237","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A238","pred":"mondo_id","subj":"T238","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A239","pred":"mondo_id","subj":"T239","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A240","pred":"mondo_id","subj":"T240","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A241","pred":"mondo_id","subj":"T241","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A242","pred":"mondo_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T546","span":{"begin":191,"end":194},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T547","span":{"begin":295,"end":303},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T548","span":{"begin":356,"end":363},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T549","span":{"begin":429,"end":436},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T550","span":{"begin":672,"end":673},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T551","span":{"begin":902,"end":905},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T25991","span":{"begin":58,"end":64},"obj":"Chemical"},{"id":"T52649","span":{"begin":143,"end":153},"obj":"Chemical"},{"id":"T63794","span":{"begin":285,"end":294},"obj":"Chemical"},{"id":"T63616","span":{"begin":635,"end":639},"obj":"Chemical"},{"id":"T46440","span":{"begin":884,"end":894},"obj":"Chemical"}],"attributes":[{"id":"A61559","pred":"chebi_id","subj":"T25991","obj":"http://purl.obolibrary.org/obo/CHEBI_16881"},{"id":"A41837","pred":"chebi_id","subj":"T25991","obj":"http://purl.obolibrary.org/obo/CHEBI_35581"},{"id":"A77654","pred":"chebi_id","subj":"T52649","obj":"http://purl.obolibrary.org/obo/CHEBI_23359"},{"id":"A49069","pred":"chebi_id","subj":"T63794","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A63175","pred":"chebi_id","subj":"T63616","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A39174","pred":"chebi_id","subj":"T46440","obj":"http://purl.obolibrary.org/obo/CHEBI_23359"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T87","span":{"begin":92,"end":120},"obj":"http://purl.obolibrary.org/obo/GO_0007019"},{"id":"T88","span":{"begin":329,"end":363},"obj":"http://purl.obolibrary.org/obo/GO_0075733"},{"id":"T89","span":{"begin":329,"end":352},"obj":"http://purl.obolibrary.org/obo/GO_0046907"},{"id":"T90","span":{"begin":343,"end":352},"obj":"http://purl.obolibrary.org/obo/GO_0006810"},{"id":"T91","span":{"begin":457,"end":485},"obj":"http://purl.obolibrary.org/obo/GO_0007019"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T54","span":{"begin":231,"end":237},"obj":"Phenotype"},{"id":"T55","span":{"begin":577,"end":591},"obj":"Phenotype"},{"id":"T56","span":{"begin":789,"end":809},"obj":"Phenotype"}],"attributes":[{"id":"A54","pred":"hp_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A55","pred":"hp_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A56","pred":"hp_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T401","span":{"begin":0,"end":4},"obj":"Sentence"},{"id":"T402","span":{"begin":5,"end":13},"obj":"Sentence"},{"id":"T403","span":{"begin":14,"end":187},"obj":"Sentence"},{"id":"T404","span":{"begin":188,"end":244},"obj":"Sentence"},{"id":"T405","span":{"begin":245,"end":456},"obj":"Sentence"},{"id":"T406","span":{"begin":457,"end":630},"obj":"Sentence"},{"id":"T407","span":{"begin":631,"end":841},"obj":"Sentence"},{"id":"T408","span":{"begin":842,"end":954},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1686","span":{"begin":375,"end":385},"obj":"Species"},{"id":"1687","span":{"begin":740,"end":750},"obj":"Species"},{"id":"1688","span":{"begin":754,"end":762},"obj":"Species"},{"id":"1689","span":{"begin":939,"end":947},"obj":"Species"},{"id":"1690","span":{"begin":45,"end":64},"obj":"Chemical"},{"id":"1691","span":{"begin":143,"end":153},"obj":"Chemical"},{"id":"1692","span":{"begin":884,"end":894},"obj":"Chemical"},{"id":"1693","span":{"begin":231,"end":237},"obj":"Disease"},{"id":"1694","span":{"begin":446,"end":455},"obj":"Disease"},{"id":"1695","span":{"begin":603,"end":623},"obj":"Disease"},{"id":"1696","span":{"begin":783,"end":818},"obj":"Disease"},{"id":"1697","span":{"begin":930,"end":938},"obj":"Disease"}],"attributes":[{"id":"A1686","pred":"tao:has_database_id","subj":"1686","obj":"Tax:2697049"},{"id":"A1687","pred":"tao:has_database_id","subj":"1687","obj":"Tax:2697049"},{"id":"A1688","pred":"tao:has_database_id","subj":"1688","obj":"Tax:9606"},{"id":"A1689","pred":"tao:has_database_id","subj":"1689","obj":"Tax:9606"},{"id":"A1691","pred":"tao:has_database_id","subj":"1691","obj":"MESH:D003078"},{"id":"A1692","pred":"tao:has_database_id","subj":"1692","obj":"MESH:D003078"},{"id":"A1693","pred":"tao:has_database_id","subj":"1693","obj":"MESH:D009369"},{"id":"A1694","pred":"tao:has_database_id","subj":"1694","obj":"MESH:D007239"},{"id":"A1695","pred":"tao:has_database_id","subj":"1695","obj":"MESH:C000657245"},{"id":"A1696","pred":"tao:has_database_id","subj":"1696","obj":"MESH:D012128"},{"id":"A1697","pred":"tao:has_database_id","subj":"1697","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"4.6. VERU-111\nIt is an orally bioavailable, 3-substituted indole derivative (Figure 8A) and microtubule depolymerization agent that recognizes colchicine-binding site on tubulin subunits. It has been under clinical development for cancer [170]. Drugs targeting microtubules have broad antiviral activity because they disrupt the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. Microtubule depolymerization agents also have strong anti-inflammatory effects that can be beneficial in mitigating the cytokine storm induced by SARS-CoV-2 infection [171]. The drug is currently being evaluated in a phase 2 randomized, placebo-controlled study for the treatment of SARS-CoV-2 in patients at elevated risk of acute respiratory distress syndrome (NCT04388826; n = 40). Of note, it is mechanistically similar to colchicine, which has also been considered in COVID-19 patients [172]."}